AMRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Amneal Pharmaceuticals Inc (AMRX) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has positive catalysts such as its inclusion in the S&P SmallCap 600 index and consistent EPS beats, the technical indicators and financial performance suggest caution. The stock lacks strong upward momentum, and the financials show significant net income decline, which could pose risks for long-term investment.
The MACD is negatively expanding, indicating bearish momentum. RSI is neutral at 44.918, and moving averages are converging, showing no clear trend. The stock is trading below the pivot level of 14.795, with support at 14.363 and resistance at 15.226, suggesting limited upward movement in the short term.
Amneal's inclusion in the S&P SmallCap 600 index enhances market recognition. The company has a strong history of beating EPS estimates (88% of the time over the past two years). Analysts have raised price targets recently, reflecting optimism.
The company has seen a significant drop in net income (-1618.59% YoY) and gross margin (-8.99% YoY). Revenue estimates have had two downward revisions in the last three months. Technical indicators do not signal strong bullish momentum.
In Q3 2025, revenue increased by 11.68% YoY to $784.51M, but net income dropped significantly by -1618.59% YoY to $2.37M. EPS remained flat at 0.01 YoY, and gross margin declined to 34.92%. The financials indicate growth in revenue but severe profitability challenges.
Analysts are optimistic about AMRX, with JPMorgan raising the price target to $18 and maintaining an Overweight rating. Truist and Barclays also have Buy and Overweight ratings, respectively, with price targets of $15. Analysts highlight opportunities in affordable medicines and easing pricing headwinds in the sector.
